One To Watch

Ajax Therapeutics

Company Overview

A Cambridge, Massachusetts-based biopharmaceutical company developing next-generation JAK inhibitors for patients with myeloproliferative neoplasms, Ajax Therapeutics agreed to be acquired by Eli Lilly for up to $2.3 billion in April 2026. Ajax was founded on the premise that existing JAK-targeted therapies, while selective for primary targets, often interact with unintended related proteins — limiting both efficacy and tolerability. The company combined structural biology with advanced computational chemistry to design highly selective JAK inhibitors intended to overcome the limitations of first-generation agents such as ruxolitinib.

Headquarters and Global Presence

Ajax Therapeutics is headquartered in Cambridge, Massachusetts, positioning it at the center of the US East Coast biotech corridor. The company operated as a privately held, US-focused organization prior to its acquisition by Indianapolis-based Eli Lilly.

Founding and History

Ajax Therapeutics was co-founded by Martin Vogelbaum, who brings more than 27 years of life sciences investment experience and has been involved in co-founding multiple biotech startups. The company established a research collaboration with Schrödinger in 2019 to leverage computational platforms alongside Ajax's structural biology capabilities. Ajax emerged from stealth in June 2024 with an oversubscribed $95 million Series C financing led by Goldman Sachs, with Eli Lilly participating as a new investor — a relationship that ultimately culminated in a full acquisition agreement announced in April 2026.

Therapy Areas and Focus

Ajax focuses exclusively on hematologic cancers, with its primary effort directed at myeloproliferative neoplasms — a group of clonal blood disorders that includes myelofibrosis, polycythemia vera, and essential thrombocythemia. Despite the approval of ruxolitinib and other first-generation JAK inhibitors, significant unmet need persists: many patients experience suboptimal responses, disease progression, and toxicities attributable to off-target kinase activity. Ajax's scientific rationale centers on the hypothesis that superior selectivity across the JAK family can yield meaningfully better clinical outcomes than currently approved agents.

Technology Platforms and Modalities

Ajax's platform integrates structural biology with Schrödinger's physics-based computational chemistry to design small-molecule JAK inhibitors with enhanced selectivity profiles. The collaboration with Schrödinger, established in 2019 and subsequently expanded to cover additional JAK targets, leverages free energy perturbation and molecular dynamics modeling to predict and optimize binding interactions before compounds enter the laboratory. This structure-guided, computation-first approach is intended to minimize off-target engagement with JAK family paralogs, directly addressing the selectivity gaps that limit marketed agents. The result is a pipeline of novel molecules designed from the ground up for precision activity within the JAK-STAT signaling pathway.

Key Pipeline and Programs

AJ1-11095 is Ajax's lead investigational asset and the program that anchored Eli Lilly's acquisition interest. It is a next-generation JAK inhibitor designed for the treatment of myeloproliferative neoplasms, with a selectivity profile engineered to improve on existing approved therapies. The compound is at an investigational clinical stage, with Lilly's press release confirming it as the primary driver of the up-to-$2.3 billion transaction. Beyond AJ1-11095, Ajax's expanded collaboration with Schrödinger added at least one additional JAK target to the research portfolio, suggesting early-stage preclinical programs in parallel. Full trial registration details and NCT identifiers for AJ1-11095 had not been publicly disclosed ahead of the Lilly acquisition announcement.

Recent Developments

In June 2024, Ajax completed an oversubscribed $95 million Series C financing led by Goldman Sachs, with Eli Lilly joining as a new investor — the company's public de-stealthing moment. On April 27, 2026, Lilly and Ajax announced a definitive acquisition agreement worth up to $2.3 billion in cash, with Cooley serving as Ajax's legal advisor. The deal represented one of the more significant MPN-focused biotech exits in recent years and extended Lilly's expanding oncology and hematology M&A strategy.

Key Personnel

Martin Vogelbaum serves as co-founder and board member of Ajax Therapeutics. He brings over 27 years of life sciences investment experience and has co-founded multiple biotech startups across stages of development. The company also recruited Srdan Verstovsek — a leading MPN clinician-scientist who has achieved international recognition for developing landmark MPN therapeutics and has led more than 60 early and advanced phase clinical trials of novel MPN drugs, including ruxolitinib — reflecting the depth of scientific and clinical leadership assembled around the JAK inhibitor program.

Strategic Partnerships

Ajax's most significant external relationship was its exclusive research collaboration with Schrödinger, initiated in 2019 and subsequently expanded to include a new JAK target, combining Schrödinger's computational platform with Ajax's structural biology expertise. Eli Lilly's participation in the Series C financing in June 2024 preceded and foreshadowed the definitive acquisition agreement announced in April 2026. The $2.3 billion deal with Lilly represents the culmination of Ajax's partnering strategy, transitioning the company's pipeline into one of the industry's largest development platforms.

FAQ Section

Lilly's acquisition of Ajax centers on AJ1-11095, a next-generation JAK inhibitor designed to surpass the efficacy and selectivity limitations of approved agents like ruxolitinib in myeloproliferative neoplasms. Lilly had already signaled its interest by participating in Ajax's $95 million Series C in June 2024 before agreeing to a full acquisition in April 2026. The deal extends Lilly's oncology and hematology M&A ambitions and adds a differentiated MPN asset to a portfolio increasingly focused on targeted cancer therapies.

First-generation JAK inhibitors, including the benchmark agent ruxolitinib, inhibit multiple JAK family members simultaneously — producing off-target effects that contribute to immunosuppression, anemia, and tolerability issues. Ajax's scientific premise is that engineering compounds with tighter selectivity profiles across JAK1, JAK2, TYK2, and JAK3 can preserve efficacy against disease-driving pathways while reducing adverse events. Improved selectivity could also support combination strategies and expand the addressable patient population beyond those who tolerate or respond to current therapy.

Ajax partnered with Schrödinger in 2019 to apply physics-based free energy perturbation modeling and molecular dynamics simulations alongside Ajax's own structural biology insights. This allows the team to predict binding affinities and selectivity profiles computationally before investing heavily in wet-lab synthesis and screening. The collaboration was expanded to cover additional JAK targets, suggesting the platform has demonstrated sufficient predictive value to underpin a broader pipeline beyond AJ1-11095.

AJ1-11095 is Ajax's lead investigational JAK inhibitor, developed for patients with myeloproliferative neoplasms including myelofibrosis and related disorders. It was cited by Eli Lilly as the primary asset driving the up-to-$2.3 billion acquisition. The compound is at an investigational stage, and its further clinical development will now be advanced under Lilly's ownership, with the company's hematology infrastructure likely accelerating its path through trials.

Ajax is focused entirely on hematologic cancers, with myeloproliferative neoplasms as the core indication — encompassing myelofibrosis, polycythemia vera, and essential thrombocythemia. The expanded Schrödinger collaboration introduced at least one additional JAK target, hinting at potential future programs within the broader MPN or hematologic malignancy space. This tight therapeutic focus allowed Ajax to build deep scientific and clinical expertise before being absorbed into Lilly's larger oncology portfolio.

Ajax emerged from stealth in June 2024 with a $95 million Series C financing, suggesting its lead program AJ1-11095 had reached a stage of development sufficient to attract significant institutional and strategic capital. The company was advancing an investigational clinical program at the time of Lilly's April 2026 acquisition announcement. Lilly's willingness to pay up to $2.3 billion for a company with a single publicly confirmed clinical-stage asset reflects the perceived differentiation of Ajax's selectivity-focused JAK platform.

With the Lilly acquisition announced in April 2026, the key watchpoints now center on deal completion and subsequent pipeline execution under new ownership. Specific items to monitor include:

Regulatory clearance and closing timeline for the Lilly acquisition
Early clinical data readouts for AJ1-11095 under Lilly's development program
Whether contingent milestone payments — part of the up-to-$2.3 billion deal structure — are triggered by clinical or regulatory outcomes
Advancement of preclinical programs arising from the expanded Schrödinger collaboration into formal development
Competitive dynamics in the MPN space, where pacritinib, fedratinib, and navitoclax combinations are also being developed

Want to Update your Company's Profile?